OneAscent Family Office LLC Has $417,000 Stock Position in Eli Lilly and Company $LLY

OneAscent Family Office LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 41.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 535 shares of the company’s stock after selling 381 shares during the period. OneAscent Family Office LLC’s holdings in Eli Lilly and Company were worth $417,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Ascent Capital Management LLC boosted its position in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after buying an additional 12 shares during the period. Willner & Heller LLC increased its stake in shares of Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock valued at $705,000 after buying an additional 13 shares during the period. Braun Bostich & Associates Inc. increased its stake in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after buying an additional 13 shares during the period. Rise Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after buying an additional 13 shares during the period. Finally, Occidental Asset Management LLC raised its position in shares of Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after acquiring an additional 13 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 2.3%

NYSE LLY opened at $927.48 on Thursday. The company has a market capitalization of $876.82 billion, a price-to-earnings ratio of 60.62, a PEG ratio of 1.21 and a beta of 0.43. The stock’s 50-day simple moving average is $792.03 and its two-hundred day simple moving average is $773.89. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $940.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.